Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, P.R. China.
Department of Laboratory Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, P.R. China.
Oncol Rep. 2021 Apr;45(4). doi: 10.3892/or.2021.7974. Epub 2021 Mar 2.
The successful application of hyperthermic intraperitoneal chemotherapy (HIPEC) illustrates its antitumor activity against primary malignances and peritoneal metastases. Although the specific underlying molecular mechanisms remain unclear, increasing evidence suggest that HIPEC directly and indirectly inhibits tumor growth, and prolongs overall survival in both hyperthermic and chemotherapeutic manners. To demonstrate the superiority and limitations of such a therapeutic regimen, the present review focuses on the biological and immunological anticancer mechanisms of HIPEC. In addition, the potential combination of HIPEC with other therapies is discussed, as well as its potential to prolong the overall survival time of patients with peritoneal malignancies.
腹腔内热灌注化疗（HIPEC）的成功应用表明其对原发性恶性肿瘤和腹膜转移具有抗肿瘤活性。尽管其具体的潜在分子机制尚不清楚，但越来越多的证据表明 HIPEC 通过热疗和化疗的方式直接和间接地抑制肿瘤生长，延长患者的总生存期。为了证明这种治疗方案的优越性和局限性，本综述重点介绍了 HIPEC 的生物学和免疫学抗癌机制。此外，还讨论了 HIPEC 与其他疗法的潜在联合应用，以及其延长腹膜恶性肿瘤患者总生存期的潜力。
